Skip to main content
SpringerLink
Log in

Osteoporosis in Rheumatologic Conditions and Inflammatory Disorders

  • Chapter
  • First Online:
Osteoporosis Rehabilitation

Abstract

The concept of inflammation-induced bone loss among patients with rheumatic diseases has gained increasing attention in the medical community in recent years. Osteoporosis may begin with inflammation but joint pain, relative immobilization with increasing loss of function, and glucocorticoid therapy also contribute substantially to evolving bone loss. A number of rheumatologic conditions including systemic sclerosis are considered noninflammatory, yet individuals with this condition and others of a similar nature are also at increased risk of osteoporosis. In this chapter, the pathogenesis, diagnosis, and epidemiology of inflammatory and noninflammatory-induced osteoporosis will be discussed with respect to several rheumatologic disorders: rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS). Management approaches, both pharmacologic and nonpharmacologic, will be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Haugenberg G, Orstovik RE, Uhlig T, Falch JA, Halse JI, Kvien TK. Clinical decision rule in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Register. Ann Rheum Dis. 2002;61:12085–9.

    Google Scholar 

  2. Hauser B, Riches PL, Wilson JF, Horne AE, Ralston SH. Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology. 2014;53(10):1759–66.

    Article  PubMed  Google Scholar 

  3. Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol. 2000;27(11):2582–9.

    CAS  PubMed  Google Scholar 

  4. Reid DM, Kennedy NS, Nicoll J, Smith MA, Tothill P, Nuki G. Total and peripheral bone mass in patients with psoriatic arthritis and rheumatoid arthritis. Clin Rheumatol. 1986;5:372–8.

    Article  CAS  PubMed  Google Scholar 

  5. Haugenberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arthritis Rheum. 2000;43:522–30.

    Article  Google Scholar 

  6. Stafford L, Bleasel J, Giles A, Handelsman D. Androgen deficiency and bone mineral density in men with rheumatoid arthritis. J Rheumatol. 2000;27:2786–90.

    CAS  PubMed  Google Scholar 

  7. Tengstrand B, Hafstrom I. Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J Rheumatol. 2002;29:2299–305.

    CAS  PubMed  Google Scholar 

  8. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum. 2000;43:2776–84.

    Article  CAS  PubMed  Google Scholar 

  9. Sinigaglia L, Varenna M, Girasole G, Bianchi G. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin N Am. 2006;32:631–58.

    Article  Google Scholar 

  10. Kaz Kaz H, Johnson D, Kerry S, Chinappen U, Tweed K, Patel S. Fall-related risk factors and osteoporosis in women with rheumatoid arthritis. Rheumatology (Oxford). 2004;43(10):1267–71.

    Article  CAS  Google Scholar 

  11. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23 Suppl 39:14–8.

    Google Scholar 

  12. Jamison M, Neuberger GB, Miller PA. Correlates of falls and fear of falling among adults with rheumatoid arthritis. Arthritis Rheum. 2003;49:673–80.

    Article  PubMed  Google Scholar 

  13. Amin S, Gabriel S, Achenbach S, Atkinson E, Melton LJ. Fracture risk is increased in young women with rheumatoid arthritis. J Bone Miner Res. 2011;26(Suppl 1):669–76.

    Google Scholar 

  14. Rodrigues Pereira RM, Freire de Carvalho J, Canalis E. Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (San Paolo). 2010;65(11):1197–205.

    Article  Google Scholar 

  15. Homik JJ, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000;2, CD000952.

    Google Scholar 

  16. Heaney RP. The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. 2005;97:13–9.

    Article  CAS  PubMed  Google Scholar 

  17. Richy F, Schact E, Bruyere O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures. Calcif Tissue Int. 2005;76:176–86.

    Article  CAS  PubMed  Google Scholar 

  18. Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF alpha antibody: a prospective open-label pilot study. Rheumatology. 2005;44:1546–8.

    Article  CAS  PubMed  Google Scholar 

  19. Dischereit G, Tarner IH, Muller-Ladner U, Lange U. Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study. Clin Rheumatol. 2013;32:377–81.

    Article  PubMed  Google Scholar 

  20. Korczowska I, Lackl JK, Hrycaj P. Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients. Yonsei Med J. 2013;54(1):183–8.

    Article  CAS  PubMed  Google Scholar 

  21. Wijbrandts CA, Klaasen R, Dijkgraaf MGW, Gerlag DM, van Eck-Smit BLF, Tak PP. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis. 2009;68:373–6.

    Article  CAS  PubMed  Google Scholar 

  22. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339:292–9.

    Article  CAS  PubMed  Google Scholar 

  23. Feng Z, Zeng S, Wang Y, Zheng Z, Chen Z. Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systemic review and meta-analysis. PLoS ONE. 2013;8(12), e80890. doi:10.1371/journal.pone.0080890.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int. 2000;11:331–7.

    Article  CAS  PubMed  Google Scholar 

  25. Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int. 2006;17:716–23.

    Article  CAS  PubMed  Google Scholar 

  26. Ebina K, Noguchi T, Hirao M, Hashimoto J, Kaneshiro S, Yukioka M, et al. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study. Osteoporos Int. 2016;27(1):351–9.

    Article  CAS  PubMed  Google Scholar 

  27. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicenter double-blind, double-dummy, randomized controlled trial. Lancet. 2009;373(9671):1253–63.

    Article  CAS  PubMed  Google Scholar 

  28. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–39.

    Article  CAS  PubMed  Google Scholar 

  29. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six month results of a randomized double-blind controlled trial. Arthritis Rheum. 2009;60(11):3346–55.

    Article  CAS  PubMed  Google Scholar 

  30. National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2013. p. 14–23.

    Google Scholar 

  31. Gennari L, Bilezekian JP. Glucocorticoid-induced osteoporosis: hope is on the HORIZON. Lancet. 2009;373(9671):1225–6.

    Article  PubMed  Google Scholar 

  32. Pedersen BK, Saltin B. Exercise as medicine-evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports. 2015;25 Suppl 3:1–72.

    Article  PubMed  Google Scholar 

  33. Lindhardsen J, Gislason GH, Ahlehoff O, Madsen OR, Hansen PR. Excess mortality from cardiovascular disease in patients with rheumatoid arthritis. Ugeskr Laeger. 2011;173:343–6.

    PubMed  Google Scholar 

  34. Hurkmans E, van der Giesen FJ, Vliet Vlieland TPM, Schoones J, Van den Ende ECHM. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis (review). Cochrane Database Syst Rev. 2009;4, CD006853.

    Google Scholar 

  35. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35(5):498–502.

    Article  CAS  PubMed  Google Scholar 

  36. de Jong Z, Munneke M, Lems WF, Zwinderman AH, Kroon HM, Jansen A, et al. Is a long term high-intensity exercise program effective and safe in patients with rheumatoid arthritis: results of a randomized controlled trial. Arthritis Rheum. 2003;48:2415–24.

    Article  PubMed  Google Scholar 

  37. Strasser B, Leeb G, Strehblow C, Schobersberger W, Haber P, Cauza E. The effects of strength and endurance training in patients with rheumatoid arthritis. Clin Rheumatol. 2011;30:623–32.

    Article  PubMed  Google Scholar 

  38. Stavropoulos-Kalinoglou A, Metsios GS, Veldhuijzen van Zanten JJ, Nightingale P, Kitas GD, Koutedakis Y. Individualized aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1819–25.

    Article  CAS  PubMed  Google Scholar 

  39. Bultink IEM, Vis M, van der Horst-Bruinsma IE, Lems WF. Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep. 2012;14:224–30.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Teichmann J, Lange U, Stracke H, Federlin K, Bretzel RG. Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol Int. 1999;18:137–40.

    Article  CAS  PubMed  Google Scholar 

  41. Garcia-Carrasco M, Mendoza-Pinto C, Escárcega RO, Jiménez-Hernández M, Etchegaray Morales I, Munguia Realpozo P, et al. Osteoporosis in patients with systemic lupus erythematosus. Isr Med Assoc J. 2009;11:486–91.

    PubMed  Google Scholar 

  42. Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005;14:106–12.

    Article  CAS  PubMed  Google Scholar 

  43. Jardinet D, Lefebvre C, Depresseux G, Lambert M, Devogelaer J-P, Houssiau FA. Longitudinal analysis of bone mineral density in pre-menopausal female systematic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology. 2000;39:389–92.

    Article  CAS  PubMed  Google Scholar 

  44. Kipen Y, Briganti E, Strauss B, Will R, Littlejohn G, Morand E. Three year followup on bone mineral density change in premenopausal women with systemic lupus erythematosus. J Rheumatol. 1999;26:310–7.

    CAS  PubMed  Google Scholar 

  45. Becker A, Fischer R, Scherbaum WA, Schneider M. Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage. Lupus. 2001;10:809–14.

    Article  CAS  PubMed  Google Scholar 

  46. Lee C, Manzi S, Ramsey-Goldman R. Bone loss and fractures in systemic lupus erythematosus. In: Maricic M, Gluck OS, editors. Bone disease in rheumatology. Philadelphia: Lippincott; 2005. p. 79–86.

    Google Scholar 

  47. Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol. 2001;28:102–8.

    CAS  PubMed  Google Scholar 

  48. Bultink IEM, Lems WF, Kostense PJ, Dijkmans BAC, Voskuyl AE. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;54:2044–50.

    Article  Google Scholar 

  49. Pons F, Peris P, Guañabens N, Font J, Huguet M, Espinosa G, Ingelmo M, Muñoz-Gomez J, Setoain J. The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. Br J Rheumatol. 1995;34(8):742–6.

    Article  CAS  PubMed  Google Scholar 

  50. Formiga F, Moga I, Nolla JM, Pac M, Mitjavila F, Roig-Escofet D. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Ann Rheum Dis. 1995;54(4):274–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 1999;42:882–90.

    Article  CAS  PubMed  Google Scholar 

  52. Zonana-Nacach A, Barr S, Magder LS, Petri M. Damage in systematic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 1999;42:1801–8.

    Google Scholar 

  53. Borba VZ, Matos PG, da Silva Viana PR, Fernandes A, Sato EI, Lazaretti-Castro M. High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus. 2005;14:529–33.

    Article  CAS  PubMed  Google Scholar 

  54. Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, Muñoz-Guarneros M, Escárcega RO, Jiménez-Hernández M, et al. Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol. 2009;28(5):579–85.

    Article  PubMed  Google Scholar 

  55. Bultink IE, Harvey NC, Lalmohamed A, Cooper C, Lems WF, van Staa TP, et al. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int. 2014;25(4):1275–83.

    Article  CAS  PubMed  Google Scholar 

  56. Genant HK, Wu CY, van Kujik C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137–48.

    Article  CAS  PubMed  Google Scholar 

  57. Sen D, Keen RW. Osteoporosis in systemic lupus erythematosus: prevention and treatment. Lupus. 2001;10:227–32.

    Article  CAS  PubMed  Google Scholar 

  58. Lambrinoudaki I, Chan DT, Lau CS, Wong RW, Yeung SS, Kung AW. Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. J Rheumatol. 2000;27:1759–65.

    CAS  PubMed  Google Scholar 

  59. Sawalha AH, Kovats S. Dehydroepiandrosterone in systemic lupus erythematosus. Curr Rheumatol Rep. 2008;10(4):286–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. van Vollenhaven RF. Dehydroepiandrosterone in systemic lupus erythematosus. Rheum Dis Clin N Am. 2000;26:349–62.

    Article  Google Scholar 

  61. van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo-controlled trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus. 1999;8(3):181–7.

    Article  PubMed  Google Scholar 

  62. Formiga F, Moga I, Nolla JM, Navarro MA, Bonnin R, Roig-Escofet D. The association of dehydroepiandrosterone sulfate levels with bone mineral density in systemic lupus erythematosus. Clin Exp Rheumatol. 1997;15(4):387–92.

    CAS  PubMed  Google Scholar 

  63. Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis Rheum. 2004;50(11):3591–5.

    Article  CAS  PubMed  Google Scholar 

  64. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled parallel-group study. Arthritis Rheum. 1999;42(11):2309–18.

    Article  CAS  PubMed  Google Scholar 

  65. Smith JA. Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep. 2015;15:489–98.

    Article  PubMed  Google Scholar 

  66. Mayo Clinic. Ankylosing spondylitis: symptoms and causes. http://www.mayoclinic.org/diseases-conditions/ankylosing-spondylitis/basics/definition/con-20019766. Accessed 10 Oct 2015.

  67. Boonen A, Severens JL. Ankylosing spondylitis: what is the cost to society, and can it be reduced? Best Pract Res Clin Rheumatol. 2002;16:691–705.

    Article  CAS  PubMed  Google Scholar 

  68. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23R induces spondyloarthropathy by acting on ROR-gamma+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18:1069–76.

    Article  CAS  PubMed  Google Scholar 

  69. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol. 2004;31(11):2236–41.

    CAS  PubMed  Google Scholar 

  70. Klingberg E, Lorentzon M, Geijer M, Gothlin J, Hilme E, Hedberg M, et al. Osteoporosis in ankylosing spondylitis-prevalence, risk factors, and methods of assessment. Arthritis Res Ther. 2012;14(R108):1–12.

    Google Scholar 

  71. Emohare O, Cagan A, Polly DW, Gertner E. Opportunistic computed tomography screening shows a high incidence of osteoporosis in ankylosing spondylitis patients with acute vertebral fractures. J Clin Densitom. 2015;18(1):17–21.

    Article  PubMed  Google Scholar 

  72. Pickhardt PJ, Pooler BD, Lauder T, del Rio AM, Bruce RJ, Binkley N. Opportunistic screening for osteoporosis using abdominal computer tomography scans obtained for other indications. Ann Intern Med. 2013;158(8):588–95.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Fatemi G, Gensler LS, Learch TJ, Weisman MH. Spine fractures in ankylosing spondylitis: a case report and review of imaging as well as predisposing factors to falls and fractures. Semin Arthritis Rheum. 2014;44(1):20–4.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Harrop JS, Sharan A, Anderson G, Hillibrand AS, Albert TJ, Flanders A, et al. Failure of standard imaging to detect a cervical fracture in a patient with ankylosing spondylitis. Spine. 2005;30(14):E417–9.

    Article  PubMed  Google Scholar 

  75. Mannerkorpi K, Hernelid C. Leisure time physical activity instrument and physical activity at home and work instrument. Development, face validity, construct validity, and test-retest reliability for subjects with fibromyalgia. Disabil Rehabil. 2005;27:695–701.

    Article  PubMed  Google Scholar 

  76. Gratacos J, Collado A, Pons F, Osaba M, Sammarti R, Roque M, et al. Significant bone mass in patients with early, active ankylosing spondylitis. Arthritis Rheum. 1999;42:2319–24.

    Article  CAS  PubMed  Google Scholar 

  77. Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int. 2001;12:605–9.

    Article  CAS  PubMed  Google Scholar 

  78. Cai G, Wang L, Fan D, Xin L, Liu L, Hy Y, et al. Vitamin D in ankylosing spondylitis: review and meta-analysis. Clin Chim Acta. 2015;438:316–22.

    Article  CAS  PubMed  Google Scholar 

  79. Krakauer T. Nuclear factor-kappaB: fine-tuning a central integrator of diverse biologic stimuli. Int Rev Immunol. 2008;27(5):286–92. doi:10.1080/08830180802317957.

    Article  CAS  PubMed  Google Scholar 

  80. Luis Neyro J, Jesus Cancelo M, Palacios S. Inhibition of RANKL in the pathophysiology of osteoporosis. Clinical evidences of its use. Ginecol Obstet Mex. 2013;81(3):146–57.

    PubMed  Google Scholar 

  81. Davey-Ranasinghe N, Deodhar A. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol. 2013;25(4):509–16.

    Article  PubMed  Google Scholar 

  82. van der Weidjen MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, Van der Horst-Bruinsma IE. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol. 2012;31:1529–35.

    Article  Google Scholar 

  83. Ghozlani I, Ghazi M, Nouijall A, Mounach A, Rezqi A, Achemlal L, et al. Prevalence and risk factors of osteoporosis and vertebral fractures. Bone. 2009;43:772–6.

    Article  Google Scholar 

  84. Wang D, Zeng Q, Chen S, Gong Y, Hou Z, Xiao Z. Prevalence and risk factors of osteoporosis in patients with ankylosing spondylitis: a 5-year follow-up study of 504 cases. Clin Exp Rheum. 2015;33(4):465–70.

    CAS  Google Scholar 

  85. Vosse D, Feldkeller E, Erlendsson J, Guesens P, vander Linden S. Clinical vertebral fractures in patients with ankylosing spondylitis. J Rheumatol. 2004;31(10):1981–5.

    PubMed  Google Scholar 

  86. El Maghraoui A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine. 2004;71:291–5.

    Article  PubMed  Google Scholar 

  87. Maksymowych WP, Jhangri GS, Leclercq S, Skeith K, Yan A, Russell AS. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol. 1998;25:714–7.

    CAS  PubMed  Google Scholar 

  88. Maksymowych WP, Lambert R, Jhangri GS, Leclercq S, Chiu P, Wong B, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol. 2001;28:144–55.

    CAS  PubMed  Google Scholar 

  89. Sargin G, Senturk T. Zoledronic acid effective as rescue treatment for ankylosing spondylitis refractory to TNF inhibition. Ann Pharmacother. 2015;49(3):368–9.

    Article  PubMed  Google Scholar 

  90. Clunie GR, Ginawi A, O’Conner P, Bearcroft W, Garber S, Bhagat S, Grainger A, Gaston JS. An open-label study of zoledronic acid (Aclasta 5 mg iv) in the treatment of ankylosing spondylitis. Ann Rheum Dis. 2014;73(6):1273–4.

    Google Scholar 

  91. Allali F, Brebon M, Porcher R, Maillefert JF, Dougados M, Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti TNF-α. Ann Rheum Dis. 2003;62:347–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Visvanathan S, van der Heijke D. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(2):175–82.

    Article  CAS  PubMed  Google Scholar 

  93. Pompeu JE, Romano RS, Pompeu SM, Lima SM. Static and dynamic balance in subjects with ankylosing spondylitis: literature review. Rev Bras Reumatol. 2012;52(3):409–16.

    Article  PubMed  Google Scholar 

  94. Del Din S, Carraro E, Sawacha Z, Guitto A, Bonaldo L, Masiero S, et al. Impaired gait in ankylosing spondylitis. Med Biol Eng Comput. 2011;49:801–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rehabilitation Medicine, Thomas Jefferson University, Philadelphia, PA, USA

    Christina V. Oleson

Authors
  1. Christina V. Oleson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina V. Oleson .

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Oleson, C.V. (2017). Osteoporosis in Rheumatologic Conditions and Inflammatory Disorders. In: Osteoporosis Rehabilitation. Springer, Cham. https://doi.org/10.1007/978-3-319-45084-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-45084-1_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-45082-7

  • Online ISBN: 978-3-319-45084-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation